Project Grant H8G47475

This $199,295 National Science Foundation project grant funded the development of a comparative online simulation tool for COVID-19 vaccine allocation strategies. Funded under the Biological Sciences program (CFDA 47.074), the Fred Hutchinson Cancer Research Center will create a mathematical model of SARS-CoV-2 transmission incorporating multiple vaccines, viral variants, and demographic factors. This model will then be used to develop a free, open-source, online comparative tool allowing up...

The National Science Foundation (NSF) awarded a $448,823 Project Grant under its Social, Behavioral, and Economic Sciences program (CFDA 47.075) to the Trustees of Boston University. This two-year grant, running from September 1, 2023 to August 31, 2025, aims to assess the effectiveness of various health communication tactics employed by federal, state, and local agencies to encourage vaccine uptake. The project will build a database of vaccine messaging from public health agencies, evaluate the...

Federal Cooperative Agreement Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital a Cooperative Agreement valued at $1.67 million under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a Phase 1 clinical study of a novel messenger ribonucleic acid (mRNA)-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. The research, initiated September 25, 2025, and scheduled for completion by July...

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

Invvax, Inc. received a $996,606 Cooperative Agreement from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective July 1, 2025, through June 30, 2027. The award supports a Small Business Innovation Research (SBIR) Phase II project focused on developing Stable Prophylactic Antibodies (SPABs) that maintain efficacy over extended periods. The primary deliverable is the creation of enhanced antibody mutations that significantly...

Viva Viral Vaccines, Inc. received a $299,968 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 25, 2025, through August 31, 2026. The project is being conducted in Ithaca, New York. The award funds development of a broad-spectrum, multivalent vaccine platform targeting influenza neuraminidase (NA) protein that addresses critical limitations in current...

The Corporation for National and Community Service awarded $381,698 under the AmeriCorps Seniors Senior Demonstration Program (CFDA 94.017) to Civic Ventures' Encore.org program. The funding will support the Encore Intergenerational Vaccine Corps initiative to address urgent COVID-19 vaccination needs in four California counties. Through this May 28, 2021 project grant, Encore.org will recruit, place, and support 325 volunteers, including 250 older adults through RSVP and 75 younger volunteers...

This federal Project Grant award of $360,000 from the National Science Foundation's (NSF) Division of Mathematical Sciences and the CDC Coronavirus and Other Respiratory Viruses Division aims to improve policymaking processes for mitigating the transmission of respiratory pathogens, such as during the COVID-19 pandemic. The principal investigators will develop and study game theoretical mathematical models, simulation tools, and numerical approaches that can be adapted to specific public...

Federal Project Grant Award Summary Massachusetts General Hospital received a $676,666 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 3, 2025, with a completion date of August 31, 2030. The award funds research into spatial and temporal adjuvant delivery mechanisms designed to enhance messenger RNA (mRNA) vaccine efficacy and durability. The project will...

The National Science Foundation Division of Environmental Biology awarded a $186,835 Project Grant to the University of Southern California Department of Contracts and Grants to support the project "RAPID: FAST COVID-19 SCENARIO PROJECTIONS IN PRESENCE OF VACCINES AND COMPETING VARIANTS" from August 1, 2021 through July 31, 2022. This funding supports research under the Biological Sciences program (CFDA 47.074), which aims to promote advancement in the biological sciences and...